ALRT
ALR TECHS INC
stock OTC

ALRT is in a great position to really starting to gain traction in the marketplace

Dexcom ($40B Mkt Cap) and Abbott ($170B Mkt Cap) only make CGMs for humans, $ALRTF just launched the first CGM for diabetic animals and partnered with the veterinary distributor Covetrus here in the US (who was recently taken private for $4B) and is selling direct to clinic in Canada.
They just released a new investor deck ([https://www.alrt.com/documents/ALRT%20Web%20Deck%202023-Q4.pdf](https://www.alrt.com/documents/ALRT%20Web%20Deck%202023-Q4.pdf)) that states they will be cash flow positive in Q1 and conduct an up-listing from the fully SEC reporting OTC.QB markets (not the same as pink-sheet markets) to the NYSE in Q1-Q2. The float is only 162 million shares and there has never been any dilution, its fully funded by the CEO and his family.
They also have the only FDA cleared diabetes management platform for human health that uses their patented predictive A1C to manage diabetes patients, and it is going to be paired with an ultra low cost CGM for humans next year.
This is a low volume stock but I expect that to change over the coming weeks and months, lots of great info on the product website [www.glucurve.com](https://www.glucurve.com), [www.GluCurve.ca](https://www.GluCurve.ca), and [www.ALRT.com](https://www.ALRT.com).
If you read through their last half a dozen or so press releases you'll see that they hired a market research firm to survey veterinarians and 97% said they would start using their GluCurve Pet CGM because the alternative is to drop the pet off at a vet clinic for 12 hours and have blood drawn and tested in a glucose meter every two hours resulting in only a handful of readings that are inaccurate due to the stress of the animal. Not only that, they cost $200-$300 and they are selling the GluCurve in Canada for around $107 USD.

ALRT is in a great position to really starting to gain traction in the marketplace

Dexcom ($40B Mkt Cap) and Abbott ($170B Mkt Cap) only make CGMs for humans, $ALRTF just launched the first CGM for diabetic animals and partnered with the veterinary distributor Covetrus here in the US (who was recently taken private for $4B) and is selling direct to clinic in Canada.
They just released a new investor deck ([https://www.alrt.com/documents/ALRT%20Web%20Deck%202023-Q4.pdf](https://www.alrt.com/documents/ALRT%20Web%20Deck%202023-Q4.pdf)) that states they will be cash flow positive in Q1 and conduct an up-listing from the fully SEC reporting OTC.QB markets (not the same as pink-sheet markets) to the NYSE in Q1-Q2. The float is only 162 million shares and there has never been any dilution, its fully funded by the CEO and his family.
They also have the only FDA cleared diabetes management platform for human health that uses their patented predictive A1C to manage diabetes patients, and it is going to be paired with an ultra low cost CGM for humans next year.
This is a low volume stock but I expect that to change over the coming weeks and months, lots of great info on the product website [www.glucurve.com](https://www.glucurve.com), [www.GluCurve.ca](https://www.GluCurve.ca), and [www.ALRT.com](https://www.ALRT.com).
If you read through their last half a dozen or so press releases you'll see that they hired a market research firm to survey veterinarians and 97% said they would start using their GluCurve Pet CGM because the alternative is to drop the pet off at a vet clinic for 12 hours and have blood drawn and tested in a glucose meter every two hours resulting in only a handful of readings that are inaccurate due to the stress of the animal. Not only that, they cost $200-$300 and they are selling the GluCurve in Canada for around $107 USD.